H.B. Fuller Co. is close to sealing a purchase of Advanced Medical Solutions Group Plc, a British maker of tissue‑healing products. The transaction values AMS equity at £628 million ($827 million). The deal signals the U.S. chemical firm’s push into the growing medical‑device market, where regenerative therapies command premium prices for investors seeking high‑growth sectors in 2024.

AMS has carved a niche in wound‑care and surgical products, positioning itself ahead of competitors in a market projected to hit $10 billion by 2028. H.B. Fuller’s core portfolio—industrial adhesives and sealants—has rarely overlapped with medical devices, making this acquisition a strategic diversification that could unlock new revenue streams for stakeholders looking to broaden their industrial footprint.

Financing the purchase will likely involve a mix of cash and stock, potentially diluting H.B. Fuller’s existing shareholders. The transaction could prompt regulatory reviews in the UK and US, as the merger blends distinct product lines and market geographies. Analysts will monitor the integration for synergies in supply chains and R&D pipelines to enhance market competitiveness.

Once closed, the deal will place H.B. Fuller among the top ten players in the UK medical‑device sector, boosting its earnings per share by an estimated 12%. Investors will see a clearer path to monetizing AMS’s patented wound‑healing technologies, while the company positions itself to capitalize on the rising demand for advanced tissue repair solutions in the next fiscal year period.